Home > Boards > US OTC > Miscellaneous >

CURE Pharmaceutical Holding Corp. (CURR)

CURR RSS Feed
Add CURR Price Alert      Hide Sticky   Hide Intro
Moderator: ProfitScout, jedijazz
Search This Board: 
Last Post: 9/20/2020 2:16:14 PM - Followers: 18 - Board type: Free - Posts Today: 0



CURE Pharmaceutical (OTCQB: CURR) is a vertically integrated drug delivery and development company 
Committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage 

CURE Pharmaceutical [OTCQB: CURR] and Canopy Growth to Produce CBD Oral Thin Films

CURR has an FDA- and DEA- registered, GMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform™ includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system.

CURR names Canopy Rivers Chairman John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience to the company, most recently serving as chairman of the Canopy Rivers board of directors and former chairman of Canopy Growth’s board of directors.

CURR offers combined technologies that provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURR partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets. The CURR company mission is to improve people’s lives by redefining how medicines are delivered and experienced.

CURR Products Fall Into Two Categories: Nutraceuticals (dietary supplements) and Pharmaceutical Medicines

Nutraceuticals:

CUREfilm® Sleep is a daily dietary supplement that delivers a unique blend of five active ingredients with the CUREfilm® platform to promote healthy sleep patterns. This product is launched in U.S. markets.

CUREfilm® D is a high-potency dietary supplement that provides 50,000 IU of Vitamin D3 delivered with the CUREfilm® platform.

CUREfilm™ Hemp delivers hemp extracts via the CUREfilm® dosage form. This product is launched in U.S. markets.

CUREfilm® β-Caryophyllene is a dietary supplement that contains 30mg of β-Caryophyllene, a powerful terpene known for its anti-inflammatory and analgesic properties.

Pharmaceuticals:

CUREfilm® Blue contains 50mg of Sildenafil delivered with the CUREfilm® platform.

CUREfilm® Canna delivers synthetic and plant-derived cannabinoids in an oral thin film for pharmaceutical indications.

CURR Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery

On February 5th CURR announced that it had signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products. The agreement grants ReLeaf Europe exclusive access to the CURR encapsulation technology for certain oral and topical cannabis products in the Netherlands, the world’s first medical cannabis market. ReLeaf Europe products will be the first to use the CUREinside™ quality mark to bolster consumer confidence. Europe is one of the world’s largest medical cannabis markets due to various governments’ approval for medicinal purposes.

ReLeaf Europe is one of the few pharmacy providers of pharmaceutical-grade medicinal cannabis oils in Europe and an ideal partner for the CURR first step into the European market because of its commitment to establishing clinical evidence and following EU GMP and GDP standards. Through this agreement, CURR will roll out its powered by CURE strategy that includes exclusive licensing relationships to build global market share.

ReLeaf Europe is tackling the largest market in the world for cannabis by establishing a foothold in Holland — a market estimated to reach $2.6B by 2028 — and by pursuing innovative delivery systems and distribution networks. CURR will power several ReLeaf Europe products, including one sublingual tincture and two topical creams to be launched in 2020.

Major Earnings Potential in the Emerging Medicinal Cannabis Industry

The Cannabis plant has an estimated 113 different compounds, out of which THC and CBD are the two main constituents. THC is mainly responsible for the psychoactive effects or the 

feeling of “high” caused by the use of cannabis. CBD on the other hand, has several powerful anti-inflammatory, analgesic, neuroprotective and anti-anxiety properties, which explains its growing popularity to treat a plethora of medical conditions. Unlike THC, CBD does not have any psychotropic effects and hence is widely preferred.

CBD is now being used to treat a wide array of medical conditions such as cancer, cardiovascular anomalies, arthritis, anxiety, depression and Insomnia. In addition, it has also been proven to possess neuroprotective benefits that can treat diseases such as seizures, Multiple Sclerosis (MS), Alzheimer’s, Parkinson’s and Schizophrenia to name a few. There is a growing preference for CBD over traditional pharmaceutical options as these have minimal side effects and are non-addictive.

The global legal marijuana market is likely to reach over USD 66.3 billion by the end of 2025, as per a report by Grand View Research, Inc, growing at a CAGR of 23.9%. There is a growing acceptance of the curative effects of cannabis, with some countries such as Canada and certain states of U.S legalizing the use of Marijuana for medical and recreational use. Research has time and again shown that cannabinoids (CBD), extracted from the cannabis plant, have varied medical uses with minimal side effects, making it a sought-after alternative to traditional pharmaceutical options.

CURR has signed a licensing and collaboration agreement with

Vanguard Scientific Systems, Inc.

Vanguard is a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions. The license gives Vanguard the right to practice CURE’s patented cannabis extraction methods, providing customer confidence in choosing Vanguard’s portfolio of extraction manufacturers

The industry is poised to grow to $2.1 billion in 2020, a 700% increase from 2016. Those numbers are not only appealing to the players in the CBD market but also serve as an incredible opportunity the pharmaceutical companies to create novel solutions for disease with large unmet medical needs. CURR is strategically positioned with multiple high value assets and extremely well-placed marketing partners to optimize the company’s earnings potential in the growing fields of key drug supply and delivery solutions, including the multi-billion-dollar CBD marketplace. For more information on CURE Pharmaceutical (OTCQB: CURR) visit: www.curepharmaceutical.com.  

CURE Pharmaceutical's CEO, Rob Davidson, on Leveraging IP for #DrugDelivery Platform and Goals for the Rest of 2020 #PoweredByCUREfilm 

  



DISCLAIMER:

Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information here. 

CURR
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CURR News: Current Report Filing (8-k) 09/24/2020 05:01:33 PM
CURR News: Quarterly Report (10-q) 08/14/2020 04:19:59 PM
CURR News: Proxy Statement (definitive) (def 14a) 08/07/2020 04:03:54 PM
CURR News: Initial Statement of Beneficial Ownership (3) 06/15/2020 06:52:50 PM
CURR News: Current Report Filing (8-k) 06/09/2020 06:56:28 AM
PostSubject
#283  Sticky Note $ CURR In a $20 Million Transaction as CURE jedijazz 07/30/20 09:00:21 AM
#240  Sticky Note $ CURR CURE Pharmaceutical Appoints Chief Business Officer jedijazz 06/16/20 08:30:31 AM
#313   Just waiting for confirmation... BlazingStocks 09/20/20 02:16:14 PM
#312   Must be getting close to closing the Sera Student of the Game 09/20/20 12:50:22 PM
#311   Great $CURR News JJ! Should provide some insight into BlazingStocks 09/02/20 08:48:38 AM
#310   News: CURE Pharmaceutical to Present at Two Virtual jedijazz 09/02/20 08:35:30 AM
#309   $CURR chart looking like the bottom is in...Let's BlazingStocks 09/01/20 08:09:23 AM
#308   Here's a preview of the article that BlazingStocks 08/24/20 12:55:40 PM
#307   $ CURR Cure Pharma is featured in MicroCap Review jedijazz 08/24/20 11:56:25 AM
#306   This is a great deal for $CURR AND BlazingStocks 08/21/20 11:24:13 AM
#305   Really nice to see CURR starting to get ProfitScout 08/21/20 11:06:25 AM
#304   Good morning $CURR. Let's have a great BlazingStocks 08/21/20 09:31:26 AM
#303   Thank you! I'll check it out! $CURR News BlazingStocks 08/19/20 08:45:18 AM
#302   These shares are clearly under accumulation and the Student of the Game 08/15/20 12:25:49 PM
#301   Likely not as the decline continues and to myearnings 08/14/20 04:53:50 PM
#300   Cure continues to decline as anticipated. myearnings 08/14/20 04:42:22 PM
#299   News: $CURR MicroCap Review Magazine Summer 2020 Issue whytestocks 08/11/20 06:15:41 PM
#298   Lots of accumulation going on!! Student of the Game 08/11/20 02:59:03 PM
#297   $CURR trying to account for all possible problems... There BlazingStocks 08/05/20 01:45:46 PM
#296   $ CURR #Undervalued #pharma https://drpgazette.com/2020/08/03/cure-pha jedijazz 08/05/20 11:11:18 AM
#295   CURE Pharmaceutical’s (OTCMKTS: $CURR ) Pharmacokinetic Study On ZoeyChay 08/04/20 02:21:02 PM
#294   $ CURR Study shows CURE’s CBD oral thin film jedijazz 08/04/20 02:19:31 PM
#293   Thanks for sharing that $CURR article! BlazingStocks 08/04/20 06:52:59 AM
#292   A MUST WATCH VIDEO INTERVIEW WITH SERA LABS CEO...........https://shoutout.wix.c Student of the Game 08/04/20 06:48:58 AM
#291   VERY informative article............ Student of the Game 08/04/20 06:47:15 AM
#290   Or they are spending money running the business...this BlazingStocks 08/03/20 02:35:08 PM
#289   good to know. point is that No One jfk 08/02/20 03:29:10 PM
#288   The insider trading rules prohibit insiders from trading Student of the Game 08/02/20 12:38:24 PM
#287   Sure...Have you seen ANY Insider buying of CURR jfk 08/01/20 01:36:22 PM
#286   This is a glimpse of where the $CURR BlazingStocks 07/31/20 12:17:22 PM
#285   $CURR News: Sera Labs, a Leader in the ZoeyChay 07/30/20 03:32:59 PM
#284   That is $1 over the current price of BlazingStocks 07/30/20 02:05:03 PM
#283   $ CURR In a $20 Million Transaction as CURE jedijazz 07/30/20 09:00:21 AM
#282   Another Rob Davidson mistake. And, he has a jfk 07/29/20 05:29:24 PM
#281   Very impressive news from CURR this week on ProfitScout 07/29/20 11:17:33 AM
#280   Huge $CURR News! MOU to acquire 100% of privately BlazingStocks 07/28/20 10:24:59 AM
#279   $CURR CURE Pharmaceutical to Acquire Sera Labs, a ZoeyChay 07/28/20 09:08:10 AM
#278   EXTREMELY TRANSFORMATIVE for CURR!!!! Great acquisition!!! Student of the Game 07/28/20 09:05:33 AM
#277   $ CURR News: CURE Pharmaceutical to Acquire Sera Labs, jedijazz 07/28/20 09:00:36 AM
#276   After reading this article: https://www.jpost.com/health-science/vitamin-d-defi Student of the Game 07/28/20 07:22:30 AM
#275   Indeed, it's good for everyone! This certification is issued BlazingStocks 07/24/20 10:51:06 AM
#274   "With the NSF-certified logo on wellness products developed jedijazz 07/24/20 09:07:38 AM
#273   $ CURR Great news as CURE Pharmaceutical Receives NSF's jedijazz 07/24/20 09:06:32 AM
#272   From $CURR News last week...huge potential! “This study indicates BlazingStocks 07/23/20 12:05:18 PM
#271   Innovative Medication Development & Enhancement Company. paytheask 07/21/20 04:30:15 PM
#270   CURE Pharmaceutical (OTCQB: CURR), based in Oxnard, CA, paytheask 07/21/20 04:28:34 PM
#269   CURR also has New Product Applications in the paytheask 07/21/20 04:28:17 PM
#268   Cure Pharmaceuticals, Inc. Stock Symbol: CURR is a paytheask 07/21/20 04:28:08 PM
#267   We keep getting very positive news indicating the ProfitScout 07/17/20 11:51:23 AM
#266   “This study indicates that CUREform technology improved cannabinoid jedijazz 07/16/20 08:20:30 AM
#265   CURE’s CEO Rob Davidson, stated, “CURE’s delivery platform, jedijazz 07/16/20 08:19:32 AM
#264   $CURR CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic StockHighAlert- 07/15/20 09:18:48 AM
PostSubject
Consent Preferences